# Noxilizer

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/noxilizer

- Industry: Healthcare
- Headquarters: US
- Website: www.noxilizer.com
- Total disclosed funding: $5M
- Latest round: Series C (Jul 27, 2009)
- Investors on record: 2

## About

Noxilizer, Inc. is a company specializing in advanced sterilization solutions using its proprietary Nitrogen Dioxide (NO2) process, designed to meet the unique sterilization needs of the pharmaceutical and medical device industries.Noxilizer, Inc. provides innovative sterilization services and equipment, focusing on the pharmaceutical and medical device sectors. Based in Baltimore, US, the company was founded by Lawrence Bruder, who has a history of involvement in related ventures. Noxilizer has participated in 8 deals, with its most recent funding round being a VENTURE DEBT of USD 150,000 in September 2013 from Industrial Growth Partners, bringing the total amount raised to USD 3.59 mn.Noxilizer, Inc. specializes in providing advanced sterilization solutions through its proprietary Nitrogen Dioxide (NO2) sterilization process, which operates efficiently within a temperature range of 10°C to 30°C. This technology is particularly well-suited for pharmaceutical, biotech, and medical device manufacturers, offering a unique, ultra-low temperature sterilization method that effectively sterilizes sensitive products, such as prefilled syringes and orthopedic implants. Noxilizer's services include both sterilization equipment sales and contract sterilization services, enabling a versatile approach to meet diverse client needs globally, including in Europe and North America.Noxilizer's revenue generation is primarily derived from the sale of its Nitrogen Dioxide sterilization technology and related services, catering to a B2B clientele in the pharmaceutical and medical device sectors. The company engages in direct sales of sterilization equipment as well as contract sterilization agreements tailored to client specifications, ensuring compliance with industry regulations. Noxilizer’s offerings include its trademarked NO2 sterilization process, recognized for its short cycle times and minimal risk of product contamination.Noxilizer, Inc. is focusing on expanding its portfolio with new sterilization product offerings aimed at enhancing operational efficiencies in the pharmaceutical sector. The company plans to explore strategic market expansions into Asia by 2025. The recent funding from the VENTURE DEBT round will support these initiatives, particularly in product development and market entry strategies.

## Funding rounds

- Series C, Jul 27, 2009, $5M — CHV Capital, Maryland Health Care Product Development Corporation

## Investors

- CHV Capital (https://capitalatlas.ai/funds/chv-capital) — Series C
- Maryland Health Care Product Development Corporation — Series C